Hims stock crumbled Tuesday after the telehealth platform issued a lackluster outlook for the current three-month period.

Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has ...

While net income remains relatively thin, the business is scaling efficientlyand doing so across a growing number of ...

Google’s chief health officer Karen DeSalvo announced she will retire this summer. DeSalvo, who likes to introduce herself as ...

Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...

Wall Street’s mood remained bound to the repercussions of Donald Trump’s trade war, with stocks moving away from session lows ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers, a digital health platform, saw subscriber growth of 38% to 2.4 million. Monthly online revenue per user also ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...